Side-effect free RNA therapeutics active only in diseased cells

SRTD biotech secures seed financing

18-Nov-2024 - Jülich-based biotech start-up SRTD biotech GmbH has successfully closed a seven-figure seed financing round. The company will use the fresh capital to accelerate the development of novel RNA therapeutics. Based on a proprietary platform technology, SRTD biotech aims to develop highly efficient ...

Collaboration between medac and start-up chiron to develop organ-on-chip technology

Further development and establishment of animal free testing methods for the pharmaceutical industry

12-Nov-2024 - Testing new substances in animals is a regulatory cornerstone of drug development. At the same time, the development of animal free testing methods is progressing. In this context the pharmaceutical company medac and the start-up chiron biotechnology are working together on the further ...

QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery

28-Oct-2024 - QUANTRO Therapeutics (QUANTRO), a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced that the company is entering into a strategic research collaboration with the group of Dr. Johannes Zuber, a world-leading expert in functional genetics and one ...

Innovative approach to treat autism spectrum disorders

University of Basel spin-off Translation-X receives Venture Kick funding

08-Oct-2024 - In 2022, Dr. Özgür Genç together with Professor Peter Scheiffele from the Biozentrum, University of Basel, founded the startup Translation-X with the goal of developing novel therapeutics for autism spectrum disorders. They have now received 150’000 Swiss Francs investment from the Venture Kick ...

Biotechnology start-up using AI to translate nature into new medicines

Enveda Biosciences announces $55M in new funding to accelerate platform and advance multiple candidates to clinical trials

19-Jun-2024 - Enveda Biosciences announced a new financing round of $55 million to add to its $119 million combined Series B and B1. New investors Premji Invest, Lingotto Investment Fund, Microsoft, and The Nature Conservancy participated in the round alongside existing investors Kinnevik, True Ventures, FPV, ...

AI designs new drugs based on protein structures

“It’s a real breakthrough for drug discovery”: Process ensures right from the start that the molecules can be chemically synthesised

25-Apr-2024 - A new computer process developed by chemists at ETH Zurich makes it possible to generate active pharmaceutical ingredients quickly and easily based on a protein’s three-​dimensional surface. The new process could revolutionise drug research. “It’s a real breakthrough for drug discovery,” says ...

Game changer in fighting cancer: BioCopy expands corporate portfolio with acquisition of start-up Perspix Biotech

"BioCopy is able to accelerate the development time from a decade long marathon to a fast sprint"

11-Apr-2024 - BioCopy AG, a research-based biotechnology company headquartered in Basel, Switzerland, announced the acquisition of Perspix Biotech GmbH. Founded in 2021 and based in Frankfurt am Main, Germany, Perspix Biotech with its end-to-end automated platform roPROTix combines artificial intelligence and ...

A new path to active ingredient diversity

26-Mar-2024 - Many important drugs, such as antibiotics and cancer drugs, are derived from natural substances from bacteria. The bacterial enzymes that produce these active ingredients are considered ideal tools for synthetic biology due to their modular design. By researching protein evolution, a team led by ...

Bayer and Aignostics to collaborate on next generation precision oncology

"Together with Bayer, we’re excited to transform AI’s immense potential into a reality for healthcare"

18-Mar-2024 - Bayer and Aignostics GmbH announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin, ...

Insamo launches with $12m funding to develop best-in-class membrane-permeable macrocyclic peptides

"Turn-key" solution from Insamo to revolutionise drug discovery

26-Feb-2024 - Insamo, a biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides, announced $12 million in seed capital from Playground Global, venBio, and MRL Ventures Fund (MRLV). MRLV is a corporate venture arm of Merck & Co., Inc which invests in ...